rediff News http://www.rediff.com/tags/astrazeneca India's largest news and entertainment service online.. en-us Thu, 28 May 15 22:16:54 +0000 Thu, 28 May 15 22:16:54 +0000 http://www.rediff.com/push Rediff feeds Copyright: (C) 2009 Rediff.com India Limited. All Rights Reserved. <![CDATA[US court rejects Ranbaxy' plea to block launch by rival cos]]> http://www.rediff.com/money/report/us-court-rejcts-ranbaxy-plea-to-block-launch-by-rival-cos/20141120.htm Fri, 29 May 2015 03:46:54 +0530 <![CDATA[AstraZeneca rejects Pfizer's final deal offer]]> http://www.rediff.com/money/report/astrazeneca-rejects-pfizers-final-deal-offer/20140519.htm Fri, 29 May 2015 03:46:54 +0530 <![CDATA[Astrazeneca rejects latest Pfizer approach]]> http://www.rediff.com/money/report/astrazeneca-rejects-latest-pfizer-approach/20140502.htm Fri, 29 May 2015 03:46:54 +0530 <![CDATA[Aurbindo Pharma inks deal with AstraZeneca]]> http://www.rediff.com/money/report/aurbindo-pharma-inks-deal-with-astrazeneca/20100906.htm Fri, 29 May 2015 03:46:54 +0530 <![CDATA[AstraZeneca India to delist scrip]]> http://www.rediff.com/money/report/astrazeneca-to-delist-scrip/20100630.htm Fri, 29 May 2015 03:46:54 +0530 <![CDATA[Nifty ends May FO at 8319; ITC, Infosys, Hero gainers]]> http://www.moneycontrol.com/news/local-markets/nifty-ends-may-fo-at-8319-itc-infosys-hero-gainers_1393700.html Fri, 29 May 2015 03:46:54 +0530 <![CDATA[Teva pays $1.2 billion to settle pay-for-delay allegations]]> http://economictimes.indiatimes.com/news/international/business/teva-pays-1-2-billion-to-settle-pay-for-delay-allegations/articleshow/47462178.cms Fri, 29 May 2015 03:46:54 +0530 <![CDATA[Catalyst Pharmaceuticals Names Richard J. Daly Interim Chief Commercial Officer]]> http://www.bizwireexpress.com/showstoryGNW.php?storyid=72857 Fri, 29 May 2015 03:46:54 +0530 <![CDATA[Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2015 Global Healthcare..]]> http://in.advfn.com/p.php?pid=nmona&article=67053863 Fri, 29 May 2015 03:46:54 +0530 <![CDATA[Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Study Commences for Patients with Two..]]> http://in.advfn.com/p.php?pid=nmona&article=67053537 Fri, 29 May 2015 03:46:54 +0530